Literature DB >> 11678896

Expansion of CD4+ T cells with a cytotoxic phenotype in patients with B-chronic lymphocytic leukaemia (B-CLL).

N Porakishvili1, T Roschupkina, T Kalber, A P Jewell, K Patterson, K Yong, P M Lydyard.   

Abstract

Abnormal CD4/CD8 ratios and T-cell function have previously been shown in patients with B-chronic lymphocytic leukaemia (B-CLL). We have demonstrated that CD4+ T cells containing both serine esterase and perforin (PF) are increased in the blood of these patients. Using flow cytometry, we have shown that the CD4+ PF+ cells were CD57+ but lacked expression of CD28, suggesting a mature population. The same phenotype in CD8+ T cells is characteristic of mature cytotoxic T cells. However, in contrast to the CD8+ T cells, the CD4+ T cells were more frequently CD45RO positive than CD45RA positive, indicating prior antigen experience. In contrast, this population lacked expression of either CD69 or HLA-DR, arguing that they were not activated or that they are an abnormal population of T cells. Their constitutive cytokine levels showed them mainly to contain IL4 and not IFNgamma, suggesting a Th2 phenotype. The role of the CD4+ PF+ T-cell population is at present uncertain. However, this potentially cytotoxic T-cell population could contribute both to enhancing survival of the B-CLL tumour cells through production of IL4, and to the immunodeficient state frequently seen in patients with this tumour, independent of drug treatment.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11678896      PMCID: PMC1906168          DOI: 10.1046/j.1365-2249.2001.01639.x

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  34 in total

1.  CD40 activation does not protect chronic lymphocytic leukemia B cells from apoptosis induced by cytotoxic T lymphocytes.

Authors:  P Chu; W G Wierda; T J Kipps
Journal:  Blood       Date:  2000-06-15       Impact factor: 22.113

Review 2.  Proapoptotic functions of cytotoxic lymphocyte granule constituents in vitro and in vivo.

Authors:  J A Trapani; J Davis; V R Sutton; M J Smyth
Journal:  Curr Opin Immunol       Date:  2000-06       Impact factor: 7.486

3.  CD4 cytotoxic and dendritic cells in the immunopathologic lesion of Sjögren's syndrome.

Authors:  G Xanthou; N I Tapinos; M Polihronis; I P Nezis; L H Margaritis; H M Moutsopoulos
Journal:  Clin Exp Immunol       Date:  1999-10       Impact factor: 4.330

4.  IL4 production and increased CD30 expression by a unique CD8+ T-cell subset in B-cell chronic lymphocytic leukaemia.

Authors:  D de Totero; G Reato; F Mauro; A Cignetti; S Ferrini; A Guarini; M Gobbi; C E Grossi; R Foa
Journal:  Br J Haematol       Date:  1999-03       Impact factor: 6.998

5.  Cytokines and chemokines in T lymphopoiesis and T-cell effector function.

Authors:  P Romagnani; F Annunziato; M P Piccinni; E Maggi; S Romagnani
Journal:  Immunol Today       Date:  2000-09

6.  Intra-tumoral cytolytic cells: pattern of distribution in B-cell non Hodgkin s lymphoma.

Authors:  S Perambakam; K Naresh; A Nerurkar; J Nadkarni
Journal:  Pathol Oncol Res       Date:  2000       Impact factor: 3.201

Review 7.  The immunomodulatory role of CD4-positive cytotoxic T-lymphocytes in health and disease.

Authors:  S Hahn; P Erb
Journal:  Int Rev Immunol       Date:  1999       Impact factor: 5.311

8.  Cytolytic T-cell responses to human dendritic cells and macrophages infected with Mycobacterium bovis BCG and recombinant BCG secreting listeriolysin.

Authors:  P Conradt; J Hess; S H Kaufmann
Journal:  Microbes Infect       Date:  1999-08       Impact factor: 2.700

9.  Loss of CD28 expression on CD8(+) T cells is induced by IL-2 receptor gamma chain signalling cytokines and type I IFN, and increases susceptibility to activation-induced apoptosis.

Authors:  N J Borthwick; M Lowdell; M Salmon; A N Akbar
Journal:  Int Immunol       Date:  2000-07       Impact factor: 4.823

10.  Human CD4(+) T lymphocytes consistently respond to the latent Epstein-Barr virus nuclear antigen EBNA1.

Authors:  C Münz; K L Bickham; M Subklewe; M L Tsang; A Chahroudi; M G Kurilla; D Zhang; M O'Donnell; R M Steinman
Journal:  J Exp Med       Date:  2000-05-15       Impact factor: 14.307

View more
  15 in total

1.  Antitumour activity mediated by CD4+ cytotoxic T lymphocytes against MHC class II-negative mouse hepatocellular carcinoma induced by dendritic cell vaccine and interleukin-12.

Authors:  Sadamu Homma; Hideo Komita; Yukiko Sagawa; Tsuneya Ohno; Gotaro Toda
Journal:  Immunology       Date:  2005-08       Impact factor: 7.397

2.  Ibrutinib is an irreversible molecular inhibitor of ITK driving a Th1-selective pressure in T lymphocytes.

Authors:  Jason A Dubovsky; Kyle A Beckwith; Gayathri Natarajan; Jennifer A Woyach; Samantha Jaglowski; Yiming Zhong; Joshua D Hessler; Ta-Ming Liu; Betty Y Chang; Karilyn M Larkin; Matthew R Stefanovski; Danielle L Chappell; Frank W Frissora; Lisa L Smith; Kelly A Smucker; Joseph M Flynn; Jeffrey A Jones; Leslie A Andritsos; Kami Maddocks; Amy M Lehman; Richard Furman; Jeff Sharman; Anjali Mishra; Michael A Caligiuri; Abhay R Satoskar; Joseph J Buggy; Natarajan Muthusamy; Amy J Johnson; John C Byrd
Journal:  Blood       Date:  2013-07-25       Impact factor: 22.113

3.  A Cross Sectional Study on T Cells and Subsets in Chronic Lymphocytic Leukemia and their Association with Clinical Phenotype.

Authors:  Mili Jain; Anushree Rai; Rashmi Kushwaha; Geeta Yadav; Sanjay Mishra; Shailendra Prasad Verma; Uma Shankar Singh; Anil Kumar Tripathi; Ashutosh Kumar
Journal:  Indian J Hematol Blood Transfus       Date:  2021-01-21       Impact factor: 0.915

4.  Intracellular expression of interleukin-4 and interferon-gamma by a Mycobacterium tuberculosis antigen-stimulated CD4+ CD57+ T-cell subpopulation with memory phenotype in tuberculosis patients.

Authors:  Maria C Jiménez-Martínez; Marisela Linares; Renata Báez; Luis F Montaño; Salvador Martínez-Cairo; Patricia Gorocica; Raúl Chávez; Edgar Zenteno; Ricardo Lascurain
Journal:  Immunology       Date:  2004-01       Impact factor: 7.397

Review 5.  Immunologic monitoring in chronic lymphocytic leukemia.

Authors:  William G Wierda
Journal:  Curr Oncol Rep       Date:  2003-09       Impact factor: 5.075

6.  Blinatumomab induces autologous T-cell killing of chronic lymphocytic leukemia cells.

Authors:  Ryan Wong; Chris Pepper; Paul Brennan; Dirk Nagorsen; Stephen Man; Chris Fegan
Journal:  Haematologica       Date:  2013-06-28       Impact factor: 9.941

7.  The PD-1/PD-L1 axis contributes to T-cell dysfunction in chronic lymphocytic leukemia.

Authors:  Davide Brusa; Sara Serra; Marta Coscia; Davide Rossi; Giovanni D'Arena; Luca Laurenti; Ozren Jaksic; Giorgio Fedele; Giorgio Inghirami; Gianluca Gaidano; Fabio Malavasi; Silvia Deaglio
Journal:  Haematologica       Date:  2013-01-08       Impact factor: 9.941

8.  Chronic lymphocytic leukemia-like monoclonal B-cell lymphocytosis exhibits an increased inflammatory signature that is reduced in early-stage chronic lymphocytic leukemia.

Authors:  Gonzalo Blanco; Anna Puiggros; Barbara Sherry; Lara Nonell; Xavier Calvo; Eulàlia Puigdecanet; Pui Yan Chiu; Yasmine Kieso; Gerardo Ferrer; Florencia Palacios; Magdalena Arnal; María Rodríguez-Rivera; Eva Gimeno; Eugènia Abella; Kanti R Rai; Pau Abrisqueta; Francesc Bosch; Alexandre Calon; Ana Ferrer; Nicholas Chiorazzi; Blanca Espinet
Journal:  Exp Hematol       Date:  2021-01-07       Impact factor: 3.249

9.  Immunogenicity of influenza vaccination in patients with non-Hodgkin lymphoma.

Authors:  Piotr Centkowski; Lidia Brydak; Magdalena Machała; Ewa Kalinka-Warzocha; Maria Błasińska-Morawiec; Irena Federowicz; Jan Walewski; Joanna Wegrzyn; Dariusz Wołowiec; Ewa Lech-Marańda; Joanna Sawczuk-Chabin; Przemysław Biliński; Krzysztof Warzocha
Journal:  J Clin Immunol       Date:  2007-03-08       Impact factor: 8.542

10.  The immune receptor Tim-3 acts as a trafficker in a Tim-3/galectin-9 autocrine loop in human myeloid leukemia cells.

Authors:  Isabel Gonçalves Silva; Laura Rüegg; Bernhard F Gibbs; Marco Bardelli; Alexander Fruehwirth; Luca Varani; Steffen M Berger; Elizaveta Fasler-Kan; Vadim V Sumbayev
Journal:  Oncoimmunology       Date:  2016-06-29       Impact factor: 8.110

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.